Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method for treating allergic rhinitis in mammals which comprises intranasally administering a pharmaceutically effective amount of a composition comprising ~~an anti-allergy agent selected from the group consisting of emedastine and~~ 0.01 – 0.8 % (w/v) olopatadine and 0.01 – 1.0 % (w/v) of a steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone, wherein the composition has a pH of 3.5 – 8.0 and a viscosity of 1 – 50 cps.

2. (cancelled).

3. (cancelled).

4. (currently amended) The method of Claim ~~3~~1 wherein the steroid is fluticasone.

5. (original) The method of Claim 1 wherein the steroid has an average particle size of 2.5 – 5 μm.

6. (original) The method of Claim 1 wherein the steroid has an average particle size of less than 0.8 μm.

7. (original) The method of Claim 6 wherein the steroid has an average particle size of 0.5 μm or less.

8. (original) The method of Claim 1 wherein the composition is an aqueous composition packaged as a nasal spray.

9. (cancelled).

10. (currently amended) A method for treating allergic rhinitis in mammals which comprises intranasally administering a pharmaceutically effective amount of a composition comprising 0.1 – 0.8 % (w/v) of olopatadine and 0.02 – 0.5 % (w/v) of a

steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone, wherein the composition has a pH of 3.5 – 8.0 and a viscosity of 1 – 50 cps., and the composition is an aqueous composition packaged as a nasal spray.